Literature DB >> 22934558

Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis.

Irit Ben-Aharon1, Anat Gafter-Gvili, Leonard Leibovici, Salomon M Stemmer.   

Abstract

BACKGROUND: Dyspnea is commonly encountered by many cancer patients in the terminal stage of their disease and it severely hampers their quality of life. We aimed to evaluate the role of interventions to alleviate dyspnea.
METHODS: Systematic review and meta-analysis of randomized controlled trials assessing all interventions for dyspnea palliation in cancer patients, and searched the Cochrane Library, MEDLINE, conference proceedings, and references.
RESULTS: Our search yielded 18 trials. Eight studies evaluated opioids in any route of administration, seven studies evaluated the use of oxygen, two studies assessed the role of benzodiazepines and two studies evaluated the role of furosemide in alleviating cancer-related dyspnea. Weighted mean difference (WMD) was calculated for continuous variables that were reported on the same scale. For continuous data reported in different scales, standardized mean difference (SMD) was calculated. Meta-analysis of three trials yielded a positive effect for opioid administration, WMD -1.31[95% CI (-2.49)-(- 0.13)]. Meta-analysis of the six studies showed lack of benefit to oxygen to improve dyspnea, SMD -0.3[95% CI -1.06-0.47]. The role of benzodiazepines remains unclear, furosemide was not beneficial.
CONCLUSIONS: Our systematic review and meta-analysis demonstrate a beneficial effect to opioids in alleviating cancer-related dyspnea, and no advantage for the use of oxygen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22934558     DOI: 10.3109/0284186X.2012.709638

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  14 in total

1.  Symptom trends in the last year of life from 1998 to 2010: a cohort study.

Authors:  Adam E Singer; Daniella Meeker; Joan M Teno; Joanne Lynn; June R Lunney; Karl A Lorenz
Journal:  Ann Intern Med       Date:  2015-02-03       Impact factor: 25.391

2.  Effects of Oral Morphine on Dyspnea in Patients with Cancer: Response Rate, Predictive Factors, and Clinically Meaningful Change (CJLSG1101).

Authors:  Kosuke Takahashi; Masashi Kondo; Masahiko Ando; Akira Shiraki; Harunori Nakashima; Hisashi Wakayama; Kensuke Kataoka; Masashi Yamamoto; Yasuteru Sugino; Mitsunori Nishikawa; Kazuyoshi Imaizumi; Eiji Kojima; Atsushi Sumida; Yoshihiro Takeyama; Hiroshi Saito; Yoshinori Hasegawa
Journal:  Oncologist       Date:  2019-01-18

3.  Effect of heated humidified high-flow nasal cannula (HFNC) oxygen therapy in dyspnea patients with advanced cancer, a randomized controlled clinical trial.

Authors:  Zhaoning Xu; Pingping Li; Chi Zhang; Dedong Ma
Journal:  Support Care Cancer       Date:  2022-08-19       Impact factor: 3.359

Review 4.  Opioids for chronic refractory breathlessness: right patient, right route?

Authors:  David C Currow; Magnus Ekstrom; Amy P Abernethy
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

5.  Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Susan Frisbee-Hume; Minjeong Park; Anne Tsao; Marvin Delgado Guay; Charles Lu; William William; Katherine Pisters; George Eapen; Frank Fossella; Sapna Amin; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2016-06-18       Impact factor: 3.612

Review 6.  Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease.

Authors:  Francesco Passiglia; Valeria Cetoretta; Marco De Filippis; Valerio Napoli; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2021-06

7.  Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults.

Authors:  Alison Haywood; Jacqueline Duc; Phillip Good; Sohil Khan; Kirsty Rickett; Petra Vayne-Bossert; Janet R Hardy
Journal:  Cochrane Database Syst Rev       Date:  2019-02-20

8.  Medication use during end-of-life care in a palliative care centre.

Authors:  Anniek D Masman; Monique van Dijk; Dick Tibboel; Frans P M Baar; Ron A A Mathôt
Journal:  Int J Clin Pharm       Date:  2015-04-09

9.  Physician-Perceived Predictive Factors for the Effectiveness of Drugs for Treating Cancer Dyspnea: Results of a Nationwide Survey of Japanese Palliative Care Physicians.

Authors:  Yoshinobu Matsuda; Ryo Matsunuma; Kozue Suzuki; Masanori Mori; Hiroaki Watanabe; Takashi Yamaguchi
Journal:  Palliat Med Rep       Date:  2020-06-30

10.  Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer.

Authors:  Frédéric Guirimand; Marine Sahut d'izarn; Lucy Laporte; Marie Francillard; Jean-François Richard; Philippe Aegerter
Journal:  Cancer Med       Date:  2015-01-30       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.